ETH is boosting its medical research and establishing a new site in Schlieren. It is currently setting up as a laboratory a newly leased building (SSA), which is in the immediate vicinity of the Wagi site and the Bio-Technopark Schlieren-Zurich. The handover is scheduled for January 2025.
According to a press release, the SSA offers a main usable area of around 7,000 sqm, with space for around eight to ten professorships and research groups in the life sciences field. The building will enable “highly efficient and flexible use” and expensive scientific equipment will be shared.
This will reportedly promote networking among the various research and industrial operations based at the Bio-Technopark sites. Specifically, ETH mentions University Hospital Zurich, the University of Zurich and the pharma company Roche. An optimal research environment is also fostered through the proximity to some medicine spin-offs based there such as Anavo medical, Acytronix and Suri BioTech.
Alongside basic biomedical research, ETH Zurich is committed to ensuring that “findings from research find rapid application in clinics and in patient care”, explained Christian Wolfrum, Vice President for Research. “As such, it also invests in translational research.” This will promote the rapid transfer of research results from basic research to practical application. mm
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space